Natália Buza

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Journal of Clinical Oncology · 2018 · 509 citations · Full text

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

Siming Zhao, Murim Choi, John D. Overton et al. · Proceedings of the National Academy of Sciences · 2013 · 333 citations · Full text

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Clinical Cancer Research · 2020 · 292 citations · Full text

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

Siming Zhao, Stefania Bellone, Salvatore Lopez et al. · Proceedings of the National Academy of Sciences · 2016 · 227 citations · Full text

Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice

Natália Buza, Diana P. English, Alessandro D. Santin et al. · Modern Pathology · 2013 · 169 citations · Full text

Endometrial Serous Carcinoma, Gynecological Surgery, Large Academic Center +7